Media headlines about Zai Lab (NASDAQ:ZLAB) have trended positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zai Lab earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.9286100203736 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities analysts have commented on the stock. J P Morgan Chase & Co assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued a “neutral” rating and a $32.00 price target for the company. Citigroup assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued a “buy” rating for the company. Finally, Leerink Swann assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued an “outperform” rating and a $42.00 price target for the company.
Zai Lab (NASDAQ ZLAB) opened at $25.74 on Thursday. Zai Lab has a 1 year low of $23.80 and a 1 year high of $35.74.
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
What are top analysts saying about Zai Lab Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zai Lab Ltd and related companies.